FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug ...
Novocure (NVCR) announced that the FDA approved its new head flexible electrode, or HFE, transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma multiforme, or ...
The spontaneous assembly of chemically encoded, molecularly crowded, water-rich micro-droplets into periodic defect-free two-dimensional arrays is achieved in aqueous media by a combination of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback